Your browser doesn't support javascript.
loading
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies.
Ramos, Rodrigo Nalio; Picanço-Castro, Virginia; Oliveira, Theo Gremen M; Mendrone, Alfredo; De Santis, Gil Cunha; Bonamino, Martin Hernan; Rocha, Vanderson.
Affiliation
  • Ramos RN; Laboratório de Investigação Médica em Patogênese e Terapia dirigida em Onco-Imuno-Hematologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil; Instituto D'Or de Ensino e Pesquisa, São Paulo, Brazil.
  • Picanço-Castro V; Fundação Hemocentro de Ribeirão Preto, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, (HC FMRPUSP) Ribeirão Preto, SP, Brazil.
  • Oliveira TGM; Laboratório de Investigação Médica em Patogênese e Terapia dirigida em Onco-Imuno-Hematologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil; Fundação Pró-Sangue-Hemocentro de São Paulo, São Paulo, Brazil.
  • Mendrone A; Fundação Pró-Sangue-Hemocentro de São Paulo, São Paulo, Brazil.
  • De Santis GC; Fundação Hemocentro de Ribeirão Preto, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, (HC FMRPUSP) Ribeirão Preto, SP, Brazil.
  • Bonamino MH; Divisão de Pesquisa Experimental e Translacional, Instituto Nacional do Câncer (INCA), Rio de Janeiro, RJ, Brazil; Vice-Presidência de Pesquisa e Coleções Biológicas da Fundação Oswaldo Cruz ((VPPCB FIOCRUZ), Rio de Janeiro, RJ, Brazil.
  • Rocha V; Laboratório de Investigação Médica em Patogênese e Terapia dirigida em Onco-Imuno-Hematologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil; Instituto D'Or de Ensino e Pesquisa, São Paulo, Brazil; Fundação Pró-Sangue-Hemocentro de São Pau
Hematol Transfus Cell Ther ; 43 Suppl 2: S46-S53, 2021 Nov.
Article de En | MEDLINE | ID: mdl-34794797
ABSTRACT
Chimeric Antigen Receptor T (CAR-T) cells are certainly an important therapy for patients with relapsed and/or refractory hematologic malignancies. Currently, there are five CAR-T cell products approved by the FDA but several research groups and/or biopharmaceutical companies are encouraged to develop new products based on CAR cells using T or other cell types. Production of CAR cells requires intensive work from the basic, pre-clinical to translational levels, aiming to overcome technical difficulties and failure in the production. At least five key common steps are needed for the manipulation of T-lymphocytes (or other cells), such as cell type selection, activation, gene delivery, cell expansion and final product formulation. However, reproducible manufacturing of high-quality clinical-grade CAR cell products is still required to apply this technology to a greater number of patients. This chapter will discuss the present and future development of new CAR designs that are safer and more effective to improve this therapy, achieving more selective killing of malignant cells and less toxicity to be applied in the clinical setting.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Pays/Région comme sujet: America do sul / Brasil Langue: En Journal: Hematol Transfus Cell Ther Année: 2021 Type de document: Article Pays d'affiliation: Brésil

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Pays/Région comme sujet: America do sul / Brasil Langue: En Journal: Hematol Transfus Cell Ther Année: 2021 Type de document: Article Pays d'affiliation: Brésil